EE03253B1 - (R)-5-karbamoüül-8-fluoro-3-N,N-diasendatud-amino-3,4-dihüdro-2H-1-bensopüraani d, nende valmistamise protsess ja neid sisaldavad ravimkoostised - Google Patents

(R)-5-karbamoüül-8-fluoro-3-N,N-diasendatud-amino-3,4-dihüdro-2H-1-bensopüraani d, nende valmistamise protsess ja neid sisaldavad ravimkoostised

Info

Publication number
EE03253B1
EE03253B1 EE9600049A EE9600049A EE03253B1 EE 03253 B1 EE03253 B1 EE 03253B1 EE 9600049 A EE9600049 A EE 9600049A EE 9600049 A EE9600049 A EE 9600049A EE 03253 B1 EE03253 B1 EE 03253B1
Authority
EE
Estonia
Prior art keywords
amino
fluoro
pharmaceutical compositions
compositions containing
benzopyran
Prior art date
Application number
EE9600049A
Other languages
English (en)
Estonian (et)
Inventor
Leslie Evenden John
Maria Hammarberg Eva (Surnud)
Sverker Hansson Hans
George Johansson Lars
Rune Michael Lundkvist Johan
Bertil Ross Svante
Dungan Sohn Daniel
Eric Hellberg Sven
Thorberg Seth-Olov
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of EE03253B1 publication Critical patent/EE03253B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EE9600049A 1993-10-28 1994-10-26 (R)-5-karbamoüül-8-fluoro-3-N,N-diasendatud-amino-3,4-dihüdro-2H-1-bensopüraani d, nende valmistamise protsess ja neid sisaldavad ravimkoostised EE03253B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/144,671 US5420151A (en) 1989-12-22 1993-10-28 Chroman derivatives
PCT/SE1994/001010 WO1995011891A1 (fr) 1993-10-28 1994-10-26 Nouveaux (r)-5-carbamyl-8-fluoro-3-amino n,n disubstitues-3,4-dihydro-2h-1-benzopyrannes

Publications (1)

Publication Number Publication Date
EE03253B1 true EE03253B1 (et) 2000-02-15

Family

ID=22509617

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9600049A EE03253B1 (et) 1993-10-28 1994-10-26 (R)-5-karbamoüül-8-fluoro-3-N,N-diasendatud-amino-3,4-dihüdro-2H-1-bensopüraani d, nende valmistamise protsess ja neid sisaldavad ravimkoostised

Country Status (36)

Country Link
US (9) US5420151A (fr)
EP (1) EP0725779B1 (fr)
JP (1) JP3089276B2 (fr)
CN (1) CN1062269C (fr)
AT (1) ATE203019T1 (fr)
AU (1) AU687115B2 (fr)
BR (1) BR9407910A (fr)
CA (1) CA2173257C (fr)
CZ (1) CZ284371B6 (fr)
DE (1) DE69427704T2 (fr)
DK (1) DK0725779T3 (fr)
EE (1) EE03253B1 (fr)
ES (1) ES2160640T3 (fr)
FI (1) FI961809A (fr)
GR (1) GR3036816T3 (fr)
HK (1) HK1002898A1 (fr)
HR (1) HRP940890B1 (fr)
HU (1) HUT75060A (fr)
IL (1) IL111365A (fr)
IS (1) IS1904B (fr)
LV (1) LV12811B (fr)
MY (1) MY111616A (fr)
NO (1) NO314146B1 (fr)
NZ (1) NZ275176A (fr)
PL (1) PL178840B1 (fr)
PT (1) PT725779E (fr)
RU (1) RU2142951C1 (fr)
SA (1) SA94150317B1 (fr)
SG (1) SG52320A1 (fr)
SI (1) SI0725779T1 (fr)
SK (1) SK280527B6 (fr)
TW (1) TW399049B (fr)
UA (1) UA44717C2 (fr)
WO (1) WO1995011891A1 (fr)
YU (1) YU49048B (fr)
ZA (1) ZA948353B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616610A (en) * 1989-12-22 1997-04-01 Astra Aktiebolag (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans
EP0498590B1 (fr) * 1991-02-08 1997-04-09 Eli Lilly And Company 2-Amino-1,2,3,4-tétrahydronaphthalènes substitués au noyau
CA2153498A1 (fr) * 1993-11-10 1995-05-18 Hidetsura Cho Derive de chromanne et utilisation therapeutique de ce dernier
SE9501567D0 (sv) 1995-04-27 1995-04-27 Astra Ab A new combination
US5990114A (en) * 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence
SE9701438D0 (sv) 1997-04-17 1997-04-17 Astra Ab A new process
SE510305C2 (sv) 1997-05-30 1999-05-10 Astra Ab Nytt salt
US7799337B2 (en) * 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
SE9703377D0 (sv) 1997-09-18 1997-09-18 Astra Ab New compounds
SE9703378D0 (sv) 1997-09-18 1997-09-18 Astra Ab New compounds
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
US6310066B1 (en) 1998-04-29 2001-10-30 American Home Products Corp. Antipsychotic indolyl derivatives
US6204274B1 (en) 1998-04-29 2001-03-20 American Home Products Corporation Indolyl derivatives as serotonergic agents
US6066637A (en) * 1998-06-19 2000-05-23 American Home Products Corporation Indolyl derivatives as serotonergic agents
WO2002055012A2 (fr) 2001-01-16 2002-07-18 Astrazeneca Ab Composes heterocycliques therapeutiques
US7032572B2 (en) * 2002-06-04 2006-04-25 Ford Global Technologies, Llc Method for controlling an engine to obtain rapid catalyst heating
SE0301796D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use II
SE0301795D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use I
US20050032873A1 (en) * 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives
US20060205807A1 (en) * 2005-02-16 2006-09-14 Wyeth Amino-chroman compounds and methods for preparing same
WO2007095586A2 (fr) * 2006-02-14 2007-08-23 The Trustees Of Columbia University In The City Of New York Modulateurs des voies de la douleur neurologique
EP2102182B1 (fr) * 2006-12-12 2014-04-23 Bial-Portela & CA, S.A. Procédé catalytique pour hydrogénation asymétrique
US8473062B2 (en) * 2008-05-01 2013-06-25 Autonomic Technologies, Inc. Method and device for the treatment of headache
US8412336B2 (en) 2008-12-29 2013-04-02 Autonomic Technologies, Inc. Integrated delivery and visualization tool for a neuromodulation system
US8494641B2 (en) 2009-04-22 2013-07-23 Autonomic Technologies, Inc. Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
US9320908B2 (en) * 2009-01-15 2016-04-26 Autonomic Technologies, Inc. Approval per use implanted neurostimulator
US20100185249A1 (en) * 2009-01-22 2010-07-22 Wingeier Brett M Method and Devices for Adrenal Stimulation
KR20190065246A (ko) 2016-07-29 2019-06-11 선오비온 파마슈티컬스 인코포레이티드 화합물 및 조성물 및 이들의 용도
CN116283877A (zh) 2016-07-29 2023-06-23 赛诺维信制药公司 化合物、组合物及其用途
CA2972203C (fr) 2017-06-29 2018-07-17 Exxonmobil Upstream Research Company Solvant de chasse destine aux procedes ameliores de recuperation
CA2974712C (fr) 2017-07-27 2018-09-25 Imperial Oil Resources Limited Methodes ameliorees de recuperation d'hydrocarbures visqueux d'une formation souterraine comme etape qui suit des procedes de recuperation thermique
SG11202000669VA (en) 2017-08-02 2020-02-27 Sunovion Pharmaceuticals Inc Isochroman compounds and uses thereof
CA2978157C (fr) 2017-08-31 2018-10-16 Exxonmobil Upstream Research Company Methodes de recuperation thermique servant a recuperer des hydrocarbures visqueux d'une formation souterraine
CA2983541C (fr) 2017-10-24 2019-01-22 Exxonmobil Upstream Research Company Systemes et methodes de surveillance et controle dynamiques de niveau de liquide
AU2020236225A1 (en) 2019-03-14 2021-09-16 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
US12007369B2 (en) * 2021-04-01 2024-06-11 Saudi Arabian Oil Company Residual corrosion inhibitor monitoring

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795874A (fr) * 1972-02-25 1973-08-23 Glaxo Lab Ltd Procede de preparation d'esters optiquement actifs d'alpha-amino-acides
JPS60152425A (ja) * 1984-01-20 1985-08-10 Oyo Seikagaku Kenkyusho:Kk ラセミ体の新規な光学分割法
US4683223A (en) * 1985-09-09 1987-07-28 Warner-Lambert Company N6 -Benzopyrano-and benzothiopyrano adenosines and methods of use
DE3679378D1 (de) * 1985-09-03 1991-06-27 Ciba Geigy Ag 3-amino-dihydro-(1)-benzopyrane und benzothiopyrane.
FR2593504B1 (fr) * 1986-01-30 1988-12-09 Ile De France Nouveaux derives de dihydrobenzofuranne - et de chromane - carboxamides, leurs procedes de preparation et leur utilisation comme neuroleptiques
US4801605A (en) * 1986-08-29 1989-01-31 Ciba-Geigy Corporation 3-amino-dihydro-[1]-benzopyrans and benzothiopyrans
SE8605504D0 (sv) * 1986-12-19 1986-12-19 Astra Laekemedel Ab Novel chroman derivatives
DE3719924A1 (de) * 1986-12-22 1988-06-30 Bayer Ag 8-substituierte 2-aminotetraline
US4971982A (en) * 1987-07-06 1990-11-20 Hoffmann-La Roche Inc. Benzopyran derivatives
US5214156A (en) * 1988-03-25 1993-05-25 The Upjohn Company Therapeutically useful tetralin derivatives
US5021432A (en) * 1988-04-26 1991-06-04 Yoshitomi Pharmaceutical Industries, Ltd. Benzopyran compound and its pharmaceutical use
CA1335591C (fr) * 1988-05-23 1995-05-16 James Arthur Nixon Derives de subtitution sur le cycle de 2-amino-1,2,3,4-tetrahydronaphtalenes
US5026707A (en) * 1988-05-23 1991-06-25 Eli Lilly And Company Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
FR2639349B1 (fr) * 1988-11-23 1991-02-22 Sanofi Sa Nouveaux derives du chromane actifs sur le systeme nerveux central, leur procede de preparation et les compositions pharmaceutiques en contenant
US5225596A (en) * 1989-01-09 1993-07-06 The Upjohn Company Halo substituted aminotetralins
IL109647A (en) * 1989-02-27 1997-04-15 Lilly Co Eli Intermediate compounds for ring-substituted 2-amino-1, 2, 3, 4-tetra- hydronaphthalenes and 3-aminochromanes
US5306830A (en) * 1989-04-27 1994-04-26 The Upjohn Company Substituted 3-amino chromans
ATE172712T1 (de) * 1989-05-31 1998-11-15 Upjohn Co Zns-wirksame 8-heterocyclyl-2-aminotetralin derivate
DE3942418A1 (de) * 1989-12-21 1991-06-27 Guenther Strecker Gestellstab
SE8904361D0 (sv) * 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
EP0471515B1 (fr) * 1990-08-15 1997-03-05 Eli Lilly And Company 2-Amino-1,2,3,4-tétrahydronaphthalènes, 3-aminochromanes et 3-aminothiochromanes au noyau
HRP920935A2 (en) * 1991-10-08 1995-08-31 Astra Ab New therapeutically active compound

Also Published As

Publication number Publication date
IL111365A0 (en) 1994-12-29
PT725779E (pt) 2001-12-28
CN1136811A (zh) 1996-11-27
ATE203019T1 (de) 2001-07-15
US5641807A (en) 1997-06-24
SK43696A3 (en) 1996-10-02
FI961809A (fi) 1996-05-20
CZ284371B6 (cs) 1998-11-11
US5656657A (en) 1997-08-12
CZ111496A3 (en) 1996-09-11
US5650524A (en) 1997-07-22
US5656658A (en) 1997-08-12
US5500425A (en) 1996-03-19
EP0725779A1 (fr) 1996-08-14
NO314146B1 (no) 2003-02-03
SK280527B6 (sk) 2000-03-13
YU62294A (sh) 1997-07-31
WO1995011891A1 (fr) 1995-05-04
US5639784A (en) 1997-06-17
NZ275176A (en) 1997-11-24
IS4226A (is) 1995-04-29
NO961687D0 (no) 1996-04-26
EP0725779B1 (fr) 2001-07-11
BR9407910A (pt) 1996-11-26
PL314086A1 (en) 1996-08-19
ES2160640T3 (es) 2001-11-16
DE69427704T2 (de) 2002-05-02
ZA948353B (en) 1995-05-02
AU8069794A (en) 1995-05-22
DE69427704D1 (de) 2001-08-16
HRP940890A2 (en) 1996-12-31
HRP940890B1 (en) 2001-12-31
US5639772A (en) 1997-06-17
UA44717C2 (uk) 2002-03-15
HK1002898A1 (en) 1998-09-25
HU9601103D0 (en) 1996-06-28
LV12811B (en) 2002-08-20
YU49048B (sh) 2003-07-07
GR3036816T3 (en) 2002-01-31
US5646309A (en) 1997-07-08
IL111365A (en) 2000-12-06
HUT75060A (en) 1997-03-28
IS1904B (is) 2003-11-20
MY111616A (en) 2000-09-27
AU687115B2 (en) 1998-02-19
PL178840B1 (pl) 2000-06-30
RU2142951C1 (ru) 1999-12-20
US5420151A (en) 1995-05-30
NO961687L (no) 1996-06-03
JPH09504287A (ja) 1997-04-28
SG52320A1 (en) 1998-09-28
SI0725779T1 (fr) 2001-12-31
LV12811A (en) 2002-04-20
JP3089276B2 (ja) 2000-09-18
CA2173257A1 (fr) 1995-05-04
FI961809A0 (fi) 1996-04-26
CN1062269C (zh) 2001-02-21
TW399049B (en) 2000-07-21
CA2173257C (fr) 2005-12-06
DK0725779T3 (da) 2001-10-29
SA94150317B1 (ar) 2005-10-15

Similar Documents

Publication Publication Date Title
EE03253B1 (et) (R)-5-karbamoüül-8-fluoro-3-N,N-diasendatud-amino-3,4-dihüdro-2H-1-bensopüraani d, nende valmistamise protsess ja neid sisaldavad ravimkoostised
NO20002788D0 (no) Nye forbindelser
BR9901491A (pt) 7-hetero-biciclo [2.2.1] - heptanos.
BG100830A (en) Naphthylamides as central nervous system agents
HUT51269A (en) Process for producing benzimidazole derivatives and pharmaceutical compositions comprising same
UA34416C2 (uk) Похідні хроману, активні стосовно 5-нт рецептора, спосіб їх одержання та проміжні сполуки
DK0556332T3 (da) Substituerede tetrahydropyridiner og hydroxypiperidiner som midler til behandling af centralnervesystemet
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
AU5835400A (en) Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and process for the preparation of the active substance
MY107354A (en) Substituted cyclohexenes as central nervous system agents
DE69804766D1 (de) Isoflavonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
UA37211C2 (uk) Похідні 1,4-дигідропіридину у формі рацемату або енантіомерів, 2-хлор-3-ціанобензальдегід як проміжний продукт для їх одержання та фармацевтична композиція, що має антагоністичну активність по відношенню до катіонів кальцію
IL115004A (en) Pharmaceutical compositions containing substituted 6-amino-4H-pyrans certain novel such compounds and their preparation

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

MM4A Lapsed by not paying the annual fees

Effective date: 20061026